BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 29, 2005
View Archived Issues
DOV Halts Ocinaplon Phase III To Check Liver Enzyme Status
Because of potential liver toxicity risks, DOV Pharmaceutical Inc. shut down a Phase III trial of its investigational anti-anxiety agent ocinaplon, a setback that could cause the company to drop the drug altogether. (BioWorld Today)
Read More
Inyx Paying UCB $37.5M To Acquire UK Subsidiary
Read More
Able Laboratories: The Rise And Fall Of A Generic Firm
Read More
Renovis' Sciatica Therapy Fizzles In Phase II Studies
Read More
Other News To Note
Read More